Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G

Saved in:

Bibliographic Details
Published in	Annals of oncology Vol. 29; p. viii201
Main Authors	Kito, Y., Yamada, T., Matsumoto, T., Yasui, H., Murata, K., Makiyama, A., Hara, H., Baba, E., Nishio, K., Yoshimura, K., Hironaka, S., Muro, K., Yamazaki, K.
Format	Journal Article
Language	English
Published	England Elsevier Ltd 01.10.2018
Online Access	Get full text

Loading…

More Information
ISSN:	0923-7534 1569-8041
DOI:	10.1093/annonc/mdy281.151